Automated retraction for thoracotomy: Improved recovery of respiratory function a
Automated retraction for thoracotomy: Improved recovery of respiratory function a
批准号:
7746190
负责人:
HUGH CHARLES CRENSHAW
金额:
$14.18万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2010-08-28
关键词:
Absence of pain sensationAgeAlgorithmsAnimalsBiomechanicsBiopsyCardiacCartilageChestChest wall structureChronicClinical ResearchClinical TrialsComputer softwareContractsDevelopmentDropsElectronicsEnsureFamily suidaeFocus GroupsFractureFrequenciesFunctional disorderGoalsHospitalsHumanKnowledgeLeadLigamentsLungManualsManufacturer NameMeasurementMeasuresMechanicsModelingMorbidity - disease rateOperative Surgical ProceduresOutcomePainPhasePostoperative PeriodPreclinical TestingProceduresRecoveryResearchRespiratory physiologyRib FracturesRoboticsSmall Business Innovation Research GrantStainless SteelSternotomySternumStressStructureSurgical InstrumentsSurgical incisionsTechnologyTestingThoracic Surgical ProceduresThoracotomyTidal VolumeTimeTissuesTrainingTranslatingTraumaUniversitiesVideo-Assisted Thoracic SurgeryWorkbehavior measurementclinically relevantdesignimprovedinstrumentmedical attentionminimally invasivenew technologypercutaneous coronary interventionpreclinical studypreventprototypepublic health relevancerespiratoryrib bone structuresurgical paintechnological innovationtechnology developmenttissue trauma
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Thoracotomies are common approaches for thoracic surgery. In 2005, approximately 200,000 were performed in the US. Thoracotomy causes significant trauma of the thoracic tissues due to mechanical separation of the ribs to create surgical access. Immediately post-surgery, respiratory function is compromised, and pain is severe, requiring significant analgesia and other medical attention. These can frequently limit release from the surgical ICU and hospital, and, most importantly, can lead to further complications. Chronic post-thoracotomy pain is also common, sometimes lasting for months or years, and is a significant contributor to morbidity. There have been extensive efforts to replace thoracotomies with minimally invasive procedures. Acceptance of most of these procedures has been low in thoracic surgery. For example, despite more than 15 years of development, thoracoscopic procedures have seen wide use only in exploration and biopsy of the lungs. For all other procedures, thoracotomies are used. In fact, the number of thoracotomies has risen by 20% over the past decade and is expected to grow dramatically as baby boomers age. Most trauma from thoracotomy occurs during spreading of the ribs by an instrument known as a "thoracic retractor". Today's thoracic retractors have had little technological innovation for nearly 70 years. Physcient, Inc. is advancing new technology, first developed at NC State University, to develop a thoracic retractor that will reduce tissue trauma in thoracotomies. Preliminary results have been positive, demonstrating that these retractors can decrease rib fractures and retraction force, greatly smooth the force of retraction, and detect imminent fractures in time to prevent them. Physcient is currently building a new prototype that combines these technologies to automate retraction. The work proposed in Phase 1 of this SBIR is to test this automated retractor against current retractors in a porcine model of thoracotomy. Primary endpoints will be reduced frequency of rib fracture, faster recovery of respiratory function (tidal volume), and faster recovery from pain (behavioral measures). Phase II of this project will begin with additional preclinical studies to ensure appropriately powered studies and then proceed to clinical trials to demonstrate efficacy of Physcient's retractor in thoracotomies in humans. PUBLIC HEALTH RELEVANCE: There are approximately 200,000 thoracotomies in the US each year. These procedures frequently are followed by significant post-operative respiratory dysfunction and pain. The goal of this project is to develop a new surgical instrument that greatly decreases respiratory dysfunction and pain after thoracotomy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: